Anaplastic Large Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Anaplastic Large Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating everolimus and lenalidomide in relapsed or refractory non-Hodgkin or Hodgkin lymphoma; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-13Clinical Trial Update: A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) [Phase 2]
Phase 2 trial update for TQ-B3101 in relapsed or refractory anaplastic large cell lymphoma (ALCL).
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A combined Phase 1/2 trial evaluating lenalidomide after chemotherapy and stem cell transplant in various forms of recurrent or resistant no…
-
CLINICAL_TRIALS trial_result · 2019-07-30Clinical Trial Update: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas [Phase 3]
Phase 3 trial comparing Brentuximab Vedotin + CHP versus standard CHOP in CD30-positive mature T-cell lymphomas completed; results posted in…
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]
Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Clinical trial update for brentuximab vedotin (Recombinant) in relapsed or refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymp…
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL [Phase 2]
Phase 2 trial evaluating belinostat combined with Yttrium-90 ibritumomab tiuxetan in relapsed aggressive B-cell non-Hodgkin lymphoma has com…
-
CLINICAL_TRIALS trial_result · 2018-06-25Clinical Trial Update: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy with pralatrexate as first-line therapy for non-Hodgkin lymphomas, including various T-cel…
-
CLINICAL_TRIALS trial_result · 2018-04-11Clinical Trial Update: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma [Phase 1]
Phase 1 study evaluating alisertib in combination with vorinostat in adults with relapsed or recurrent Hodgkin lymphoma, B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms [Phase 1]
Phase 1 study of brentuximab vedotin given sequentially and in combination with multi-agent chemotherapy for CD30-positive mature T-cell and…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
-
CLINICAL_TRIALS trial_result · 2017-05-17Clinical Trial Update: Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer [Phase 2]
Phase 2 trial evaluating haploidentical donor bone marrow transplantation in patients with high-risk hematologic cancers; results completed …
-
CLINICAL_TRIALS trial_result · 2017-05-15Clinical Trial Update: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]
A pediatric Phase 1/2 study of brentuximab vedotin (ADCETRIS) in relapsed or refractory systemic anaplastic large cell lymphoma or Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a conditioning regimen with Iodine-131 tositumomab plus etoposide and cyclophosphamide, followed by autolo…
-
CLINICAL_TRIALS trial_result · 2016-05-19Clinical Trial Update: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
This clinical trial update reports on biomarker expression in samples from young patients with anaplastic large cell lymphoma, offering insi…
-
CLINICAL_TRIALS trial_result · 2016-03-10Clinical Trial Update: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial sponsored by the National Cancer Institute evaluated alisertib for relapsed or refractory peripheral T-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma [Phase 1]
This document reports Phase 1 results from a trial in relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. T…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial update for MORAb-004 in young patients with recurrent or refractory solid tumors or lymphoma; the study has been completed.
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating sorafenib tosylate in patients with recurrent aggressive non-Hodgkin lymphomas has completed, with results posted i…
-
CLINICAL_TRIALS trial_result · 2015-08-13Clinical Trial Update: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
Phase 1 study evaluating the combination of methoxyamine and fludarabine phosphate in adults with relapsed or refractory hematologic maligna…
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma [Phase 2]
An update on the completed Phase 2 study of SGN-30, an anti-CD30 monoclonal antibody, in patients with refractory or recurrent anaplastic la…
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) [Phase 1]
Phase 1 pharmacology study update of Brentuximab vedotin (SGN-35) has completed, according to clinical trials data. The study involves patie…
-
CLINICAL_TRIALS trial_result · 2014-12-18Clinical Trial Update: Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies [Phase 1]
Phase I open-label dose-finding study of SGN-35 (brentuximab vedotin) for CD30-positive hematologic malignancies, including non-Hodgkin lymp…